SNBR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SNBR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near 1.81 in pre-market, but the broader setup is weak: the latest quarter showed a major revenue decline, a large EPS loss, suspended guidance, and a legal investigation. Technicals are not confirming a durable reversal, and analyst sentiment remains only Neutral with aggressive price target cuts. I would not buy this now.
Current price action is weak despite a small positive MACD histogram reading. RSI_6 at 48.5 is neutral, so momentum is not oversold enough to signal a strong rebound. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which points to a downtrend rather than a trend reversal. Price is near the pivot at 1.683, with resistance at 1.852 and 1.955 and support at 1.515 and 1.412. The pre-market price of 1.81 is still below first resistance, and the recent stock trend estimate suggests only limited short-term upside with weaker monthly performance.
["MACD histogram is slightly positive and expanding, which can indicate early short-term stabilization.", "Stock trend model suggests a 60% chance of a small move higher over the next day and next week.", "Pre-market price is holding near the pivot level, which may attract short-term traders."]
["Q1 2026 revenue fell 18.9% year over year.", "Reported GAAP EPS of -2.19, reflecting severe earnings weakness.", "Financial guidance was suspended.", "Stock dropped 22.45% after earnings.", "Legal investigation into possible securities fraud adds major overhang.", "Analysts have sharply cut price targets from 10 to 4 and then to 2.", "Trend remains bearish with SMA_200 > SMA_20 > SMA_5.", "Hedge funds and insiders show no notable bullish accumulation."]
Latest quarter: Q1 2026. The company reported a steep 18.9% year-over-year revenue decline and GAAP EPS of -2.19. Guidance was suspended, which is a major negative for visibility into future growth. The quarter does not show healthy growth trends; instead, it shows shrinking sales, weak profitability, and deteriorating confidence.
Analyst sentiment is Neutral but clearly deteriorating. UBS cut its price target from 10 to 4 and then again from 4 to 2 while keeping a Neutral rating. Piper Sandler also lowered its target to 5 from 12, citing that marketing spend and new product launches have not yet improved sales. Wall Street’s pro view is that the company may be making some operational progress, but the con view is much stronger: sales are still falling, guidance is suspended, and target cuts show declining confidence. Politicians or influential figures: no recent buying or selling data. Congress trading: no recent congress trading data available.
